WallStSmart

Artivion Inc (AORT)vsGE HealthCare Technologies Inc. (GEHC)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

GE HealthCare Technologies Inc. generates 4573% more annual revenue ($20.63B vs $441.33M). GEHC leads profitability with a 10.1% profit margin vs 2.2%. GEHC appears more attractively valued with a PEG of 1.70. GEHC earns a higher WallStSmart Score of 60/100 (C+).

AORT

Hold

39

out of 100

Grade: F

Growth: 6.7Profit: 4.5Value: 2.0Quality: 5.0

GEHC

Buy

60

out of 100

Grade: C+

Growth: 4.0Profit: 7.0Value: 7.3Quality: 4.3
Piotroski: 2/9Altman Z: 1.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AORTSignificantly Overvalued (-2704.2%)

Margin of Safety

-2704.2%

Fair Value

$1.43

Current Price

$36.12

$34.69 premium

UndervaluedFair: $1.43Overvalued
GEHCSignificantly Overvalued (-156.0%)

Margin of Safety

-156.0%

Fair Value

$30.94

Current Price

$72.20

$41.26 premium

UndervaluedFair: $30.94Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AORT1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
19.2%8/10

19.2% revenue growth

GEHC2 strengths · Avg: 8.5/10
Return on EquityProfitability
22.4%9/10

Every $100 of equity generates 22 in profit

P/E RatioValuation
15.6x8/10

Attractively priced relative to earnings

Areas to Watch

AORT4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$1.73B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
2.7%3/10

ROE of 2.7% — below average capital efficiency

Profit MarginProfitability
2.2%3/10

2.2% margin — thin

GEHC4 concerns · Avg: 2.8/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

Piotroski F-ScoreQuality
2/93/10

Weak financial health signals

EPS GrowthGrowth
-17.7%2/10

Earnings declined 17.7%

Altman Z-ScoreHealth
1.342/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AORT

The strongest argument for AORT centers on Revenue Growth. Revenue growth of 19.2% demonstrates continued momentum.

Bull Case : GEHC

The strongest argument for GEHC centers on Return on Equity, P/E Ratio.

Bear Case : AORT

The primary concerns for AORT are EPS Growth, Market Cap, Return on Equity. A P/E of 172.0x leaves little room for execution misses. Thin 2.2% margins leave little buffer for downturns.

Bear Case : GEHC

The primary concerns for GEHC are PEG Ratio, Piotroski F-Score, EPS Growth.

Key Dynamics to Monitor

AORT profiles as a growth stock while GEHC is a value play — different risk/reward profiles.

AORT carries more volatility with a beta of 1.64 — expect wider price swings.

AORT is growing revenue faster at 19.2% — sustainability is the question.

GEHC generates stronger free cash flow (917M), providing more financial flexibility.

Bottom Line

GEHC scores higher overall (60/100 vs 39/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Artivion Inc

HEALTHCARE · MEDICAL DEVICES · USA

Artivion Inc. manufactures, processes and distributes implantable human tissues and medical devices worldwide.

GE HealthCare Technologies Inc.

HEALTHCARE · MEDICAL DEVICES · USA

GE HealthCare Technologies Inc. provides medical technology, pharmaceutical diagnostics, and digital solutions in the United States. The company is headquartered in Chicago, Illinois.

Want to dig deeper into these stocks?